Joshua Bomsztyk
Overview
Explore the profile of Joshua Bomsztyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, et al.
Amyloid
. 2024 Sep;
31(4):353-355.
PMID: 39311543
No abstract available.
2.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf M, Foard D, et al.
Br J Haematol
. 2024 Jun;
205(1):138-145.
PMID: 38840512
Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second-line daratumumab-bortezomib-dexamethasone (DVD) in AL amyloidosis in bortezomib-exposed patients. A total of 116 patients...
3.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, et al.
Haematologica
. 2024 Jan;
109(5):1598-1602.
PMID: 38205538
No abstract available.
4.
Bomsztyk J, Ravichandran S, Giles H, Wright N, Berlanga O, Khwaja J, et al.
Blood
. 2024 Jan;
143(13):1259-1268.
PMID: 38194690
Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry-based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC assays...
5.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, et al.
Br J Haematol
. 2024 Jan;
204(5):1811-1815.
PMID: 38171355
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate,...
6.
Rauf M, Hawkins P, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al.
Eur Heart J
. 2023 Mar;
44(24):2187-2198.
PMID: 36946431
Aims: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio...
7.
Uppal E, Khwaja J, Bomsztyk J, McCarthy H, Kothari J, Walton P, et al.
Br J Haematol
. 2023 Jan;
201(5):905-912.
PMID: 36698318
National registries are used globally to characterise patient demographics, treatment choices and mortality to inform and improve clinical management. Waldenström macroglobulinaemia (WM) is a rare, treatment-responsive B-cell lymphoproliferative disorder with...
8.
Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, et al.
Blood Cancer J
. 2022 Sep;
12(9):128.
PMID: 36064540
No abstract available.
9.
Bomsztyk J, Khwaja J, Wechalekar A
Expert Rev Hematol
. 2022 Aug;
15(9):781-788.
PMID: 36039749
Introduction: High-dose melphalan followed by autologous stem cell transplant (ASCT) has been transformative in treating AL amyloidosis since the early nineties. Recently, the European Hematology Association (EHA) and International Society...
10.
Crossette-Thambiah C, Pericleous C, Asmar N, Bomsztyk J, Ranger A, Shlebak A, et al.
J Neurol Neurosurg Psychiatry
. 2021 Sep;
93(4):445-448.
PMID: 34588182
No abstract available.